Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
RDNT
SELLRadNet, Inc. · Healthcare · United States · $4.8B · Avg Vol: $57M/d
COMPANY DESCRIPTION
RadNet, Inc. is the largest provider of freestanding outpatient diagnostic imaging services in the United States, offering a comprehensive range of MRI, CT, PET/CT, mammography, and X-ray services. The company's competitive advantage lies in its expansive network of centers, significant scale, and integration of AI-powered solutions to enhance diagnostic accuracy and operational efficiency. It plays a critical role in delivering accessible and advanced imaging care.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 1.4B | 1.6B | 1.8B | 2.0B | 12.6% | 2.1B | 2.5B | 2.7B | 16.0% |
| EPS | 0.47 | 0.19 | 0.05 | 0.04 | -0.25 | -56.0% | -0.16 | — | — | — |
| Shares | — | 57.7M | 68.0M | 74.0M | 77.4M | +34.1% | 78.6M | — | — | — |
| Debt | — | 1.5B | 1.5B | 1.7B | 1.9B | 7.1% | 1.9B | — | — | — |
| Equity | — | 333.0M | 630.7M | 902.3M | 1.1B | 48.5% | — | — | — | — |
| Op CF | — | 146.4M | 220.9M | 233.0M | 298.8M | 26.8% | 336.3M | — | — | — |
| Inv CF | — | -246.9M | -201.5M | -233.1M | -343.9M | — | — | — | — | — |
| Fin CF | — | 93.6M | 195.6M | 397.9M | 72.2M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of RDNT are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| RDNT | RadNet, Inc.(you) | $4.8B | 31 | SELL |
| BLLN | BillionToOne, Inc. | $5.8B | 41 | HOLD |
| TWST | Twist Bioscience Corporation | $5.6B | 44 | HOLD |
| ADPT | Adaptive Biotechnologies Corporation | $3.6B | 44 | HOLD |
| GRAL | GRAIL, Inc. | $2.9B | 19 | STRONG SELL |
| NEO | NeoGenomics, Inc. | $1.8B | 45 | HOLD |
| PSNL | Personalis, Inc. | $1.3B | 24 | SELL |
| SHC | Sotera Health Company | $4.9B | 66 | BUY |
| OPK | OPKO Health, Inc. | $921M | 35 | HOLD |
| WGS | GeneDx Holdings Corp. | $1.8B | 14 | STRONG SELL |
Peer medians: ROE -25.6% · P/E 27.6x · Gross margin 50.6%